Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

Chi-Med Completes US Offering at Lowered Price of $13.50/ADS

publication date: Mar 17, 2016
Hutchison China MediTech (Chi-Med) raised $101.5 million by pricing its initial US offering at a disappointing $13.50 per ADS, which is 17% lower than the expected price of $16.33. The size of the offering was increased from 6.1 million ADSs to 7.5 million, keeping the gross proceeds from the transaction just above the $100 million target. During today's London trading session, Chi-Med's ordinary shares also fell 17% as the price of the US offering was announced. In its first hours of US trading, Chi-Med's stock traded lower to $13.20. More details....

Stock Symbols: (NSDQ: HCM; AIM: HCM)

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes


Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital